Paul K. Audhya Sells 8,077 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock traded down $0.07 during trading on Wednesday, reaching $8.98. The company's stock had a trading volume of 165,768 shares, compared to its average volume of 482,817. The company has a market capitalization of $388.12 million, a price-to-earnings ratio of -2.56 and a beta of 0.92. The stock's 50-day moving average price is $11.10 and its 200 day moving average price is $12.03. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.39 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.91) by $0.04. On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in KalVista Pharmaceuticals in the second quarter valued at approximately $25,000. EntryPoint Capital LLC purchased a new position in shares of KalVista Pharmaceuticals during the first quarter worth about $92,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock worth $96,000 after buying an additional 3,328 shares during the last quarter. Intech Investment Management LLC acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $126,000. Finally, SG Americas Securities LLC purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at approximately $153,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on KALV shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC reiterated a "buy" rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).